29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer ("PROC") who progressed on a median of 7 prior lines of therapy

Cytokine Release Syndrome ("CRS") in PROC limited to Grade 1 in 11% of patients

Pharmacokinetic ("PK") profile supports exploration of Q3W dosing in 2H 2026

CTIM-76 has been granted FDA Fast Track Designation in PROC

Company to host conference call on Monday, June 15 at 8:00 a.m. ET

PHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced positive interim Phase 1 clinical data for its CLDN6 x CD3 T cell engaging bispecific antibody, CTIM-76, in advanced, late-line platinum-resistant ovarian cancer ("PROC"). The data are as of a May 29, 2026 data cutoff from the ongoing CTIM-76 Phase 1 study.